Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Naveen Lobo (NPI 1023025434)

Field	Value
Entity Type	Individual
Organization	Naveen Lobo
Address	1310 14th Ave Se
City	Decatur
State	AL
ZIP	35601
Taxonomy	Medical Oncology Physician
NPI Enumerated	August 1, 2006

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider’s billing footprint is effectively single-payer Medicare: lifetime Medicare revenue is $2.4M and there is no Medicaid billing on file, so analyses of service mix and utilization should be interpreted in the context of a Medicare-dominated practice rather than a dual-payer operation. The absence of Medicaid claims suggests limited engagement with state programs or a patient panel concentrated in the Medicare population.

Revenue is highly concentrated in a small set of biologic and infusion codes: the precomputed top 3 Medicare codes (J9271, J1568, J0897) account for 62.9% of this provider’s Medicare revenue, with J9271 (pembrolizumab) alone producing $946K (40.7% of Medicare revenue). This concentration indicates that a few high-cost biologics drive the bulk of billings.

The CPT/HCPCS mix identifies an infusion-centric oncology practice delivering immunotherapy and supportive biologics: J9271 (pembrolizumab), J1568 (Octagam immune globulin), and J0897 (denosumab) are the top revenue drivers, and chemotherapy and infusion administration codes such as 96413 (784 claims, $72.1K), 96417 (244 claims, $11.2K), G0498 (184 claims, $29.6K), and 96365 (437 claims, $19.7K) appear throughout the top codes. Together, these patterns are consistent with an outpatient infusion operation that couples high-cost oncologic drugs with clinic-based administration and monitoring.

Competitive standing is mixed across specific services: for the top drug J9271 the provider ranks #308 of 1841 (83rd percentile) and is described as a typical, unremarkable national participant for that code, whereas several administration and supportive drug codes are extreme outliers or notably above typical volumes—examples include J1454 (rank #7 of 422, 99th percentile, extreme outlier), G0498 (rank #11 of 896, 99th percentile, extreme outlier), and 96372 (rank #406 of 58224, 99th percentile, extreme outlier). This suggests the provider is not uniquely dominant for pembrolizumab nationally but operates a locally high-volume infusion/service platform for certain add-on drugs and administration services.

Supportive care and anemia management are important revenue lines: iron infusion J1437 accounts for $151.6K (6.5% of Medicare revenue) and ranks #41 of 581 (93rd percentile, notably above typical), and epoetin biosimilar Q5106 contributes $52.1K (2.2%) and ranks #45 of 695 (94th percentile, notably above typical). The presence of multiple iron and erythropoiesis-stimulating product codes (including J0885 and J1750) indicates routine management of treatment-related anemia and iron deficiency alongside oncologic therapy.

High volumes of monitoring and lab services are billed in support of active infusion care: CBC and phlebotomy codes such as 85025 (3.2K claims, $25.8K; rank #520 of 32833, 98th percentile) and 36415 (3.2K claims, $25.4K; rank #520 of 86467, 99th percentile) plus lab panels 80053 and tests like 82728 and 82607 all appear in the top codes. These patterns point to an on-site monitoring workflow with frequent lab-based follow-up accompanying infusion treatments.

This provider shows long tenure in the Medicare program, with an NPI enumeration date of 2006-08-01 (~20 years ago), which supports the likelihood of an established outpatient oncology practice and built-up referral/infusion infrastructure over time. The longevity combined with concentrated biologic revenue suggests stability in delivering specialty oncology infusions to a Medicare population.

Although a few drug codes (e.g., J0642 at rank #1 of 6, 100th percentile) show unique national rank positions, the plain-English characterizations in the data must guide interpretation: some high-rank positions are labeled as typical or unremarkable while others are labeled extreme outliers. Analysts should therefore treat each code individually—recognizing that while the practice is not universally dominant for all high-cost oncology drugs, it does report several extreme or notably above-typical volumes for administration and select supportive agents, indicating a focused operational emphasis on infusion services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

80 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	22,000	$40	$946K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	8,030	$30	$265K
J0897	Injection, denosumab, 1 mg	13,980	$20	$251.6K
J1437	Injection, ferric derisomaltose, 10 mg	8,920	$20	$151.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,350	$90	$121.6K
J0642	Injection, levoleucovorin (khapzory), 0.5 mg	119,950	$1	$120K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	780	$90	$72.1K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	210	$340	$69.9K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	8,680	$10	$52.1K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	180	$160	$29.6K

Showing 1–10 of 80

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 80 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Naveen Lobo — 16 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

80 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	30	19,900	$40	$827.2K
J1568	10	30	5,180	$30	$316.2K
J0897	14	200	3,120	$20	$97.7K
J0642	1	10	81,310	$1	$81.3K
J1437	3	40	3,000	$20	$59.1K
J1439	10	10	41,250	$1	$39K
J1454	2	20	90	$340	$33.7K
J0885	3	10	3,660	$10	$32.3K
Q5106	1	10	2,650	$10	$23.6K
96413	3	150	150	$90	$20.2K

Showing 1–10 of 80

Related Providers

Other providers that share a Tax Identification Number (TIN) with Naveen Lobo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Robert Conry	AL	Hematology & Oncology Physician	$2.1M	$0
Lakshmikanth Katragadda	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M
Surrinder Dang	AL	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Naveen Lobo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hawkins Mccaghren Partnership	AL	General Practice Dentistry	$0	$13.5M
Encore Rehabilitation, Inc	AL	Physical Therapy Clinic/Center	$0	$8.3M
Sunbridge Home Health Care, Inc.	AL	In Home Supportive Care Agency	$0	$7.8M
H H Health System-morgan LLC	AL	General Acute Care Hospital	$0	$6.9M
Decatur Morgan Pediatrics	AL	Pediatrics Physician	$0	$3.6M
Riverside Family Health LLC	AL	Family Nurse Practitioner	$0	$3.3M
Decatur Morgan Emergency Medicine	AL	Emergency Medicine Physician	$0	$2.9M
Encore Rehabilitation, Inc.	AL	Physical Therapy Clinic/Center	$0	$2.6M
Hh Health System - Dmh Ambulance LLC	AL	Land Ambulance	$1.1M	$1.4M
Heather Shah	AL	Hematology & Oncology Physician	$1.8M	$0

Naveen Lobo — Billing Profile & Reimbursement Data

Sign up for Naveen Lobo — Billing Profile & Reimbursement Data policy alerts

Naveen Lobo — Billing Profile & Reimbursement Data

Sign up for Naveen Lobo — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References